Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739112 · ClinicalTrials.gov registry record · Phase 3
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
A Phase 3 study, sponsored by Medicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 12,794
- Enrollment target
NCT03739112 is a Phase 3 study that has completed, run by Medicago. The registered enrollment target is 12,794 participants.
The verdict
NCT03739112, a Phase 3 study, has completed, sponsored by Medicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12,794 participants
- Enrollment target
Study Summary
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.
Interventions
- BIOLOGICAL Quadrivalent VLP Vaccine
- BIOLOGICAL Fluarix Quadrivalent® Comparator Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,794 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739112
The ClinicalTrials.gov registry entry for NCT03739112 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12,794 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicago, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quadrivalent VLP Vaccine is the first listed.
NCT03739112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03739112 about?
NCT03739112 is a clinical study titled "Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly". This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain)...
What is the current status of trial NCT03739112?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,794 participants. The study started on 2018-09-18. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT03739112?
The interventions under investigation include: Quadrivalent VLP Vaccine (BIOLOGICAL), Fluarix Quadrivalent® Comparator Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03739112?
This trial is sponsored by Medicago, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.